33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy - European Lung Cancer Congress 2019

33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy

Translational research

33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy

Authors

K. Gennen (Munich, Germany)
L. Käsmann (Munich, Germany)
C. Eze (Munich, Germany)
M. Dantes (Munich, Germany)
O. Roengvoraphoj (Munich, Germany)
J. Taugner (München, Germany)
J. Neumann (München, Germany)
A. Tufman (Munich, Germany)
M. Orth (München, Germany)
S. Reu (Würzburg, Germany)
C. Belka (Munich, Germany)
F. Manapov (Munich, Germany)

Speakers

K. Gennen (Munich, Germany)

Previous ePoster

31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer

Next ePosters

35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population

36P - Can a BALF profile distinguish hot vs cold lung tumors?

38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells

41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis

44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative

45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative

46P - Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

48P - Education and lung cancer: A Mendelian randomisation study

49P - A Mendelian randomization study of the effects of Crohn’s disease on lung cancer